These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16405565)

  • 1. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
    Lens M
    Dermatol Ther; 2006; 19(1):9-18. PubMed ID: 16405565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
    Agarwala SS; Gray RJ; Wong MK
    J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
    [No Abstract]   [Full Text] [Related]  

  • 3. An update on adjuvant interferon for melanoma.
    Gray RJ; Pockaj BA; Kirkwood JM
    Cancer Control; 2002; 9(1):16-21. PubMed ID: 11907462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
    Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
    Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
    Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
    J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant melanoma: non-metastatic.
    Crosby D; Crosby T; Mason M
    Clin Evid; 2002 Jun; (7):1519-29. PubMed ID: 12230768
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
    Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
    Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
    Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
    J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials.
    Wheatley K; Ives N; Hancock B; Gore M; Eggermont A; Suciu S
    Cancer Treat Rev; 2003 Aug; 29(4):241-52. PubMed ID: 12927565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
    Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N
    Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
    Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
    J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical management of cutaneous melanoma: current practice and impact on prognosis.
    Mosca PJ; Tyler DS; Seigler HF
    Adv Surg; 2004; 38():85-119. PubMed ID: 15515616
    [No Abstract]   [Full Text] [Related]  

  • 18. Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.
    Ascierto PA; Daponte A; Parasole R; Perrone F; Caracò C; Melucci M; Palmieri G; Napolitano M; Mozzillo N; Castello G
    Cancer; 2000 Oct; 89(7):1490-4. PubMed ID: 11013362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant melanoma. Less recurrence with interferon].
    MMW Fortschr Med; 2001 Feb; 143(5):55. PubMed ID: 11236804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.